Bio-Rad Laboratories, Inc. Class A Common Stock vs Warner Music Group Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Warner Music Group Corp trades at $27.69 (market cap $14.38B). The key difference: Warner Music Group Corp is the larger of the two by market cap, and Warner Music Group Corp pays a 2.76% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WMG | |
|---|---|---|
Market Cap | $8.04B | $14.38B |
Sector | Health | Media |
52-Week High | $339.75 | $34.72 |
52-Week Low | $241.71 | $23.65 |
Enterprise Value | $7.85B | $18.58B |
Dividend Yield | — | 2.76% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Warner Music Group (WMG) trades at $28.75, down 0.83% today, with a bullish technical signal and strong analyst consensus. Recent financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. The company maintains solid profitability with a 45.8% gross margin and recently acquired AI startup Sureel AI to enhance intellectual property management. Cash flow from operations remains healthy at $678M despite a net cash outflow of $159M in 2025.
WMG offers upside with a $40.40 consensus price target (40.5% potential) and 66.7% buy ratings, supported by streaming growth and AI initiatives. Risks include competitive pressures, margin volatility, and reliance on music industry trends. The stock's high P/E of 34.23 requires sustained earnings acceleration to justify valuation.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →